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Th e prevalence of diabetes mellitus is increasing, in part 
due to aging, obesity, and lower levels of physical activity. 
Th e ﬁ ndings of Siegelaar and colleagues presented in the 
previous issue of Critical Care challenge current beliefs 
but are also relevant to all [1]. Advanced diabetes is 
associated with end organ damage that is likely to impact 
upon critically ill patients – nephropathy, autonomic 
neuropathy, and small-vessel and large-vessel disease. 
Th us many believe that diabetes is associated with 
increased mortality and morbidity in patients admitted 
to an intensive care unit (ICU). Moreover, studies have 
demonstrated that not addressing severe hyperglycaemia 
(>10  mmol/l) in critically ill patients is associated with 
higher mortality [2,3].
Siegelaar and colleagues use meta-analysis techniques 
to examine the relationship between mortality and 
diabetes mellitus in patients admitted to an ICU. Pooling 
data from 141 studies and nearly 12.5  million patients, 
they demonstrate that, outside the cardiothoracic ICU, 
diabetes mellitus is not associated with an increased risk 
of mortality. Th eir ﬁ ndings were consistent whether 
mortality was con sidered at ICU discharge, hospital 
discharge, or 28/30 days.
Th e value of the study lies in the large number of 
patients included, sourced from a broad range of publi-
cations most of which were not speciﬁ c to patients with 
diabetes mellitus. Moreover, the Forest plots demon strate 
consistency between studies. However, unmeasured con-
founders may inﬂ uence their results. Whilst a sensitivity 
analysis using risk-adjusted mortality from ﬁ ve studies 
encompassing ~15% of the patients demonstrates a 
similar result, the model is not comprehensive. For 
example, patients with diabetes mellitus may receive 
inhibitors of the renin–angiotensin system, HMG-CoA 
reductase inhibitors, peroxisome proliferator-activated 
recep tor gamma agonists, and aspirin. All of these 
treatments have been postulated to aﬀ ect outcome in 
critically ill patients [4-6]. Th e study is limited also by 
considering diabetes mellitus as a homogeneous entity 
rather than a diagnosis that encompasses two diﬀ erent 
pathophysio logies and widely ranging therapies and 
qualities of glycaemic control. How all these parameters 
impact upon outcome is not explored.
Th e authors’ results are mirrored in current risk-
adjustment models. In the cardiothoracic setting, the 
presence of diabetes mellitus has been used as a risk 
factor for perioperative mortality in the Parsonnet score 
[7] but not the EuroSCORE tools [8]. Cardiac revas cu-
larisation of patients with diabetes mellitus is complicated 
by poorer targets and microvascular disease. By contrast, 
diabetes mellitus does not form part of standard ICU 
risk-prediction models such as the Acute Physiology and 
Chronic Health Evaluation score and the Simpliﬁ ed 
Acute Physiology Score [9-12].
Why does the presence of diabetes mellitus not matter 
outside the cardiothoracic ICU? As the authors point 
out, the higher incidence of sepsis in patients with 
diabetes mellitus may imply a protective eﬀ ect. Certainly, 
targeting mild hyperglycaemia in all patients seems 
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prefer able to strict normoglycaemia control [13]. Th e 
eﬀ ects of insulin may be detrimental in the critically ill 
[14]. Insulin is anti-inﬂ ammatory [15] and switches cells 
to preferentially metabolise glucose rather than free fatty 
acids. Alterna tively, patients with diabetes mellitus may 
be taking protective medications or have become accus-
tomed to mild hyperglycaemia, a prooxidant status, or 
increased levels of advanced glycated end products – all 
implicated in the pathogenesis of systemic inﬂ ammation.
Since few would have cited diabetes mellitus as a 
contri butory reason for deﬁ ning an ICU admission as 
futile, Siegelaar and colleagues’ study does not change 
our clinical practice. Nevertheless, the suggestion of a 
potential protective eﬀ ect for diabetes mellitus merits 
further investigation. Unpicking this hypothesis may 
reveal new therapeutic strategies that we can exploit in 
other patient populations.
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